Literature DB >> 9875140

Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma.

A Väisänen1, M Kallioinen, P J Taskinen, T Turpeenniemi-Hujanen.   

Abstract

The penetration of the subepithelial basement membrane is the first critical step in the dissemination of melanoma. In vitro studies have suggested that the 72 kD type IV collagenase (MMP-2) may be important in melanoma invasion. It has recently been demonstrated that the expression of MMP-2 immunoreactive protein increased with increasing atypia in melanocytic tumours and was associated with later haematogenous metastases in melanoma. This paper investigates the value of MMP-2 as a possible prognostic marker in melanoma. The expression of MMP-2 immunoreactive protein was studied with immunoperoxidase staining in paraffin-embedded sections of 50 cases of primary skin melanoma by using specific, affinity purified antibodies. Positive immunostaining was quantified by counting the percentage of positive cancer cells and was compared with clinical patient characteristics and survival. Sixty-four per cent of the primary melanoma cases displayed positive cytoplasmic immunostaining for MMP-2 in tumour cells. Marked overexpression of MMP-2 protein (> or = 34 per cent of melanoma cells positive) correlated with the 5-year survival of the patients when compared with patients with lower MMP-2 positivity, 55 per cent vs. 85 per cent, respectively (P < 0.05). Male patients displayed positive staining more often than females (75 per cent vs. 54 per cent, respectively). There was no correlation between MMP-2 positivity and Clark level or Breslow classification. A distinct group with unfavourable prognosis was identified. The 10-year survival for MMP-2-positive male melanoma patients was 39 per cent as opposed to 79 per cent with the other melanoma patients (P < 0.05). In the hierarchic Cox regression model for survival, MMP-2 immunoreactive protein was found to be independent of Clark level and Breslow classification. Overexpression of MMP-2 protein indicated a 4.5-fold relative risk of dying from melanoma. It is concluded that MMP-2 immunoreactive protein in melanoma cells is an independent prognostic factor for survival. High MMP-2 expression in male melanoma patients indicates an unfavourable prognosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9875140     DOI: 10.1002/(SICI)1096-9896(199809)186:1<51::AID-PATH131>3.0.CO;2-P

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  24 in total

Review 1.  Matrix metalloproteinase biology applied to vitreoretinal disorders.

Authors:  C S Sethi; T A Bailey; P J Luthert; N H Chong
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

2.  Variability in melanoma metalloproteinase expression profiling.

Authors:  Orsi Giricz; Janelle L Lauer; Gregg B Fields
Journal:  J Biomol Tech       Date:  2010-12

3.  Melanoma prognostic model using tissue microarrays and genetic algorithms.

Authors:  Bonnie E Gould Rothberg; Aaron J Berger; Annette M Molinaro; Antonio Subtil; Michael O Krauthammer; Robert L Camp; William R Bradley; Stephan Ariyan; Harriet M Kluger; David L Rimm
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

4.  An inhibitor of stress-activated MAP-kinases reduces invasion and MMP-2 expression of malignant melanoma cells.

Authors:  Carsten Denkert; Antje Siegert; Anja Leclere; Andreas Turzynski; Steffen Hauptmann
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 5.  Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.

Authors:  Eleonore Fröhlich
Journal:  Cell Mol Life Sci       Date:  2010-08-05       Impact factor: 9.261

6.  MMP-21 is upregulated at early stages of melanoma progression but disappears with more aggressive phenotype.

Authors:  Tiina Kuivanen; Katja Ahokas; Susanna Virolainen; Tiina Jahkola; Erkki Hölttä; Olli Saksela; Ulpu Saarialho-Kere
Journal:  Virchows Arch       Date:  2005-08-20       Impact factor: 4.064

7.  Expression of MMP-2,TIMP-2 protein and the ratio of MMP-2/TIMP-2 in gallbladder carcinoma and their significance.

Authors:  Yue-Zu Fan; Jing-Tao Zhang; Hu-Chuan Yang; Yao-Qin Yang
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

8.  Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis.

Authors:  Pawan Kumar; Arti Yadav; Samip N Patel; Mozaffarul Islam; Quintin Pan; Sofia D Merajver; Theodoros N Teknos
Journal:  Mol Cancer       Date:  2010-08-03       Impact factor: 27.401

9.  Annexin A1 in primary tumors promotes melanoma dissemination.

Authors:  Zied Boudhraa; Fabien Rondepierre; Lemlih Ouchchane; Roselyne Kintossou; Anna Trzeciakiewicz; Frederic Franck; Jean Kanitakis; Bruno Labeille; Juliette Joubert-Zakeyh; Bernadette Bouchon; Jean Luc Perrot; Sandrine Mansard; Janine Papon; Pierre Dechelotte; Jean-Michel Chezal; Elisabeth Miot-Noirault; Mathilde Bonnet; Michel D'Incan; Françoise Degoul
Journal:  Clin Exp Metastasis       Date:  2014-07-06       Impact factor: 5.150

10.  Downregulation of matrix metalloproteinase-2 (MMP-2) utilizing adenovirus-mediated transfer of small interfering RNA (siRNA) in a novel spinal metastatic melanoma model.

Authors:  Andrew J Tsung; Odysseas Kargiotis; Chandramu Chetty; Sajani S Lakka; Meena Gujrati; Daniel G Spomar; Dzung H Dinh; Jasti S Rao
Journal:  Int J Oncol       Date:  2008-03       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.